TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $131.80.

Several research analysts have commented on the company. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Tuesday. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research note on Tuesday. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Piper Sandler cut their target price on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Finally, JPMorgan Chase & Co. lowered their price target on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,958 shares of company stock valued at $3,470,328 over the last 90 days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in TransMedics Group by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock worth $139,680,000 after purchasing an additional 23,979 shares during the last quarter. Driehaus Capital Management LLC lifted its stake in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares during the period. Geode Capital Management LLC grew its holdings in shares of TransMedics Group by 1.3% during the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after buying an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the period. Finally, Vaughan Nelson Investment Management L.P. raised its stake in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Down 16.1 %

Shares of TMDX opened at $71.44 on Friday. The firm has a fifty day moving average price of $108.52 and a 200-day moving average price of $135.34. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm has a market capitalization of $2.40 billion, a P/E ratio of 76.00 and a beta of 2.06. TransMedics Group has a 12-month low of $68.84 and a 12-month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period last year, the firm earned ($0.12) earnings per share. Equities research analysts expect that TransMedics Group will post 1.01 earnings per share for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.